IDEXX Laboratories, Inc.
IDXXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, IDEXX Laboratories, Inc. focuses on Diagnostics & Research services and products. IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company carries a $44.20B market cap, placing it firmly in the large-cap category. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Market Cap
$44.20B
Beta
1.55
P/E (TTM)
39.38
P/E (Fwd)
33.41
EPS (TTM)
$14.23
EPS (Fwd)
$16.77
ROE
74.2%
ROA
27.1%
Cash
$196.9M
Total Debt
$1.10B
Free CF
$909.4M
52W Change
-13.4%
Annual Financials
Cash vs Debt
Where IDXX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IDXX finished 0.45% above its 150-day moving average ($553.29) and 4.02% below its 200-day moving average ($579.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IDXX overbought or oversold?
At the October 20, 2026 close, IDXX's RSI(14) was 60.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
IDEXX Laboratories, Inc. carries $1.10B in total debt against $196.9M in cash reserves — debt is roughly 5.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $909.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 74.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 27.1% further supports the picture of efficient asset utilization. Revenue has grown from $3.37B (2022) to $4.30B (2025), reflecting a 28% increase over the period.
With a beta above 1.5, IDXX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing IDXX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.